Qiagen NV and TScan Therapeutics are collaborating to develop T cell-based laboratory tests for detecting prior exposure to SARS-CoV-2 using TScan’s T-Scan T cell receptor (TCR) target discovery platform.
Under the terms of the agreement, announced on 10 November, Qiagen has secured an option to license the rights to...